{"id":304951,"date":"2026-10-13T11:58:10","date_gmt":"2026-10-13T06:28:10","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=304951"},"modified":"2026-10-13T11:58:10","modified_gmt":"2026-10-13T06:28:10","slug":"oral-rehydration-global-generic-and-pharmacy-chain-stocks-next-phase-spotlight","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/oral-rehydration-global-generic-and-pharmacy-chain-stocks-next-phase-spotlight\/","title":{"rendered":"3 Oral Rehydration, Global Generic and Pharmacy Chain Stocks With a Strong Future Roadmap: FDC, Aurobindo Pharma and Medplus Health Services"},"content":{"rendered":"

FDC Rs 341.40, P\/E 18.05. Aurobindo Pharma Rs 1,706.90, P\/E 25.46. Medplus Rs 627.60, P\/E 36.06. Closing prices of 12 Oct 2026.<\/em><\/p>\n

\n

Quick Answer<\/strong><\/p>\n

Oral rehydration, global generic and pharmacy chain stocks with the clearest long-term roadmaps today include FDC in oral rehydration products with eye, ear and anti-infective formulations, Aurobindo Pharma in generic formulations and active ingredients for global markets and Medplus in a pharmacy retail chain across several states. FY26 revenue growth was 3.9% at FDC, 5.6% at Aurobindo Pharma and 12.6% at Medplus. P\/E stands at 18.05 for FDC (industry 37.59), 25.46 for Aurobindo Pharma (industry 37.59) and 36.06 for Medplus (industry 66.59). Demand cycles, input costs and valuation decide how much of that growth the market keeps paying for, so each company’s risks need equal attention.<\/p>\n<\/p><\/div>\n

Oral rehydration, global generic and pharmacy chain stocks give investors exposure to medicines and pharmacy stores that patients and global buyers rely on. Prescription growth, export approvals and store additions decide how much of that demand turns into profit.<\/p>\n

This list covers three oral rehydration, global generic and pharmacy chain stocks: FDC for oral rehydration products with eye, ear and anti-infective formulations, Aurobindo Pharma for generic formulations and active ingredients for global markets and Medplus Health Services for a pharmacy retail chain across several states. Every figure comes from the latest reported financials and the 12 October 2026 market close. Companies without complete current figures were left out.<\/p>\n

Click Here – Get Free Investment Predictions<\/strong><\/a><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n